Dr. Brian J. Druker is one of the most influential figures in modern cancer medicine. An American physician-scientist based in Portland, Oregon, he is widely recognized for helping transform the treatment of chronic myeloid leukemia (CML), a blood cancer that was once extremely difficult to manage.
His pioneering work helped establish a new approach to cancer treatment known as precision medicine, in which therapies are designed to target specific molecular abnormalities responsible for disease.
Dr. Druker serves as a professor of medicine at Oregon Health & Science University (OHSU) and president of the Knight Cancer Institute. He also holds the JELD-WEN Chair of Leukemia Research.
Education and Early Medical Career
Dr. Druker earned his medical degree from the University of California, San Diego, in 1981.
He subsequently completed his internship and residency at Washington University School of Medicine in St. Louis before pursuing fellowship training in medical oncology at Dana-Farber Cancer Institute and Harvard Medical School.
After joining OHSU in 1993, he began developing research programs focused on understanding the molecular mechanisms behind leukemia and identifying more effective ways to treat the disease.
The Breakthrough That Changed Leukemia Treatment
Dr. Druker’s most recognized contribution is his role in developing imatinib, commercially known as Gleevec.
His research focused on an abnormal protein called BCR-ABL, which drives the growth of cancer cells in chronic myeloid leukemia.
Rather than attacking all rapidly dividing cells, his research helped establish the possibility of targeting this specific cancer-causing protein.
Gleevec became one of the most important examples of targeted cancer therapy. Its introduction dramatically improved outcomes for many patients with CML, transforming a disease that had often been life-threatening into one that could frequently be managed with medication.
This breakthrough helped inspire the development of many other targeted cancer treatments.
Continuing Research and Medical Innovation
Dr. Druker continues to contribute to cancer research through the Knight Cancer Institute at OHSU.
His broader research interests include understanding the genetic and molecular mechanisms of blood cancers, identifying treatment resistance, and developing more personalized therapies.
His research group has continued publishing work on leukemia biology and treatment. In 2026, his publication record included research involving DDX41-mutated acute myeloid leukemia, another serious blood cancer.
The goal of this research is to better understand how specific genetic mutations influence cancer development and treatment outcomes.
A Major Investment in the Future of Cancer Care
In 2025, OHSU announced a historic $2 billion commitment from philanthropists Phil and Penny Knight to support the next phase of the Knight Cancer Institute.
Dr. Druker is helping lead this ambitious initiative, which aims to strengthen cancer research, improve early detection, expand access to innovative clinical trials, and create a more integrated experience for patients.
The investment represents a major opportunity to accelerate scientific discoveries and bring promising research closer to clinical practice.
Recognition and Lasting Influence
Dr. Druker’s achievements have earned some of the highest honors in medicine, including the Lasker-DeBakey Clinical Medical Research Award, the Japan Prize, the Tang Prize, and the Sjöberg Prize. He is also a member of the National Academy of Medicine and the National Academy of Sciences.
His career demonstrates how understanding the molecular foundations of disease can completely change the way physicians approach treatment.
Through his research, leadership, and commitment to advancing cancer medicine, Dr. Brian Druker continues to influence the future of oncology and inspire a new generation of physician-scientists.
